• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Chief Scientific Officer Pinkas Jan

    7/16/25 7:11:26 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CBIO alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Pinkas Jan

    (Last) (First) (Middle)
    C/O/ CRESCENT BIOPHARMA, INC.
    300 FIFTH AVENUE

    (Street)
    WALTHAM MA 02451

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    CRESCENT BIOPHARMA, INC. [ CBIO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Scientific Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    07/16/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $13.14 07/16/2025 A 142,474 (1) 07/16/2035 Ordinary Shares 142,474 $0.00 142,474 D
    Explanation of Responses:
    1. This option will vest as to 25% on July 7, 2026 and in equal monthly installments thereafter through July 7, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
    /s/ Barbara Bispham, as attorney-in-fact for Jan Pinkas 07/16/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CBIO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CBIO

    DatePrice TargetRatingAnalyst
    8/11/2025$25.00Buy
    H.C. Wainwright
    7/14/2025$27.00Outperform
    Wedbush
    6/25/2025$28.00Buy
    Stifel
    11/15/2021Outperform → Market Perform
    Raymond James
    8/6/2021$19.00 → $18.00Outperform
    Raymond James
    More analyst ratings

    $CBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Scientific Officer Pinkas Jan

    4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)

    7/16/25 7:11:26 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Pinkas Jan

    3 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)

    7/15/25 4:16:24 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Luo Ying acquired 2,840,376 shares (SEC Form 4)

    4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)

    11/22/23 7:55:53 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

    Completed Merger with GlycoMimetics and Previously Announced $200 Million Private Financing Supporting Pipeline of Next Generation Therapeutics for Solid Tumors Recent Leadership Appointments Bring Deep Experience in Oncology Drug Development, Clinical Operations and Building Biotechnology Companies On Track to Submit IND Application for CR-001, a PD-1 x VEGF Bispecific Antibody, in Fourth Quarter of 2025, with Proof-of-Concept Clinical Data Expected in Second Half of 2026 WALTHAM, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer pat

    7/31/25 7:34:20 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer

    Seasoned Leader Brings Deep Experience in Oncology Drug Development as Company Advances Portfolio of Next Generation Therapeutics for Solid Tumors WALTHAM, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced the appointment of Jan Pinkas, Ph.D., as chief scientific officer. Dr. Pinkas brings more than two decades of experience in oncology drug development, leading preclinical and translational research with expertise in multiple modalities, including antibody-drug conjugates (ADCs). "We are thrilled to welcome Ja

    7/8/25 7:30:00 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million

    Advancing Lead Program, CR-001, a PD-1 x VEGF Bispecific Antibody, and Developing Pipeline of Novel ADCs as Single Agents and in Combination with CR-001 On Track to Submit IND Application for CR-001 in Fourth Quarter of 2025 with Proof-of-Concept Clinical Data Expected in Second Half of 2026 Shares to Begin Trading on Nasdaq Under Ticker Symbol "CBIO" Today, June 16 WALTHAM, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company"), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced the completion of its previously announced merger with GlycoMimetics, Inc. ("GlycoMimetics"). The com

    6/16/25 7:00:00 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Crescent Biopharma with a new price target

    H.C. Wainwright initiated coverage of Crescent Biopharma with a rating of Buy and set a new price target of $25.00

    8/11/25 10:02:50 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wedbush initiated coverage on Crescent Biopharma with a new price target

    Wedbush initiated coverage of Crescent Biopharma with a rating of Outperform and set a new price target of $27.00

    7/14/25 8:50:29 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Crescent Biopharma with a new price target

    Stifel initiated coverage of Crescent Biopharma with a rating of Buy and set a new price target of $28.00

    6/25/25 7:56:35 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CBIO
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Crescent Biopharma Inc.

    SCHEDULE 13G/A - CRESCENT BIOPHARMA, INC. (0001253689) (Subject)

    8/14/25 4:01:23 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crescent Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - CRESCENT BIOPHARMA, INC. (0001253689) (Filer)

    7/31/25 7:36:17 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Crescent Biopharma Inc.

    10-Q - CRESCENT BIOPHARMA, INC. (0001253689) (Filer)

    7/31/25 7:25:56 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CBIO
    Financials

    Live finance-specific insights

    View All

    Catalyst Biosciences Completes First Steps in Reverse Merger Plan

    Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction Announces $7.5 Million Special Dividend and Contingent Value Right (CVR) CBIO Stockholder Meeting Planned for 2023 CBIO to Host Conference Call Today at 8:00 a.m. E.T. SOUTH SAN FRANCISCO, Calif. and TOKYO, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) ("Catalyst") and GNI Group Ltd. (2160.T) ("GNI") today announced that the parties have signed definitive agreements for the sale and purchase of GNI's proprietary new chemical entity F351 program. F351 has shown clinical efficac

    12/27/22 7:00:00 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Catalyst Biosciences, Inc. Announces September 21, 2022 as the Ex-Dividend Date for Special Cash Dividend of $1.43 per share

    SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) ("Catalyst," the "Company" or "we") today announced that the ex-dividend date for the special, one-time cash dividend of $1.43 per share to holders of the Company's Common Stock previously disclosed by the Company will be September 21, 2022. The dividend is payable on September 20, 2022 to stockholders of record at the close of business on September 6, 2022. Stockholders of record on the record date who sell their shares prior to the ex-dividend date will not receive the special dividend. The aggregate amount of the payment to be made in connection with this special dividend will be app

    9/1/22 4:05:00 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Catalyst Biosciences, Inc. Declares Special Cash Dividend of $1.43 per share

    SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) ("Catalyst," the "Company" or "we") today announced that the Board of Directors has declared a special, one-time cash dividend of $1.43 per share to holders of the Company's Common Stock. The dividend is payable on September 20, 2022 to stockholders of record at the close of business on September 6, 2022. The aggregate amount of the payment to be made in connection with this special dividend will be approximately $45 million. The Company anticipates that it may declare one or more additional special dividends in the future, although there can be no assurance that such distributions will

    8/25/22 8:00:00 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CBIO
    Leadership Updates

    Live Leadership Updates

    View All

    Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer

    Seasoned Leader Brings Deep Experience in Oncology Drug Development as Company Advances Portfolio of Next Generation Therapeutics for Solid Tumors WALTHAM, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced the appointment of Jan Pinkas, Ph.D., as chief scientific officer. Dr. Pinkas brings more than two decades of experience in oncology drug development, leading preclinical and translational research with expertise in multiple modalities, including antibody-drug conjugates (ADCs). "We are thrilled to welcome Ja

    7/8/25 7:30:00 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

    EMERYVILLE, Calif., Dec. 15, 2023 /PRNewswire/ -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent libraries and AI tools, announced today that Nassim Usman, Ph.D., has been named President & Chief Executive Officer and closed a $66M Series B financing led by DCVC Bio. Neil Dhawan, Ph.D, Totus co-founder, founding CEO, and CSO, will transition into a new role as CSO and Head of R&D, where he will continue to oversee the company's platform, programs, and data. "We are thrilled by Nassim's arrival," said DCVC Bio Managing Pa

    12/15/23 9:04:00 AM ET
    $CBIO
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Catalyst Biosciences Sends Letter to Stockholders

    Reiterates the Board's Commitment to Expeditiously Distributing All of the Company's Available Cash to Stockholders, Net of Liabilities and Obligations Warns Stockholders that JDS1 May Have Ulterior Motives in Running a Proxy Contest: Gaining Control of the Company's Cash and Other Assets for JDS1's Own Benefit Stockholders Urged to VOTE "FOR" ALL of Catalyst's Nominees, Who Are Committed to the Company's Cash Distribution Plan, on the WHITE Proxy Card SOUTH SAN FRANCISCO, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) (the "Company" or "we") today announced that it mailed a letter to its stockholders in connection with the Company's upcoming 2022 Ann

    7/19/22 8:00:00 AM ET
    $CBIO
    $EVOL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    EDP Services
    Technology

    $CBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Catalyst Biosciences Inc. (Amendment)

    SC 13G/A - GYRE THERAPEUTICS, INC. (0001124105) (Subject)

    2/14/24 1:18:41 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Catalyst Biosciences Inc. (Amendment)

    SC 13D/A - GYRE THERAPEUTICS, INC. (0001124105) (Subject)

    1/24/24 5:11:14 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Catalyst Biosciences Inc. (Amendment)

    SC 13D/A - GYRE THERAPEUTICS, INC. (0001124105) (Subject)

    11/27/23 4:49:38 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care